Monday, October 12, 2015
The Pulse on Site Success by Jeffrey Adelglass
If it has not become apparent to you over the last few years that the landscape is changing regarding the importance of a perspective site’s offer to sponsors and CROs, then one might infer you are missing the opportunity to better position your site for recognition and success.
Quintiles and Quest Diagnostics have launched Q2 Solutions, a new combined clinical trials laboratory services organization. Q2 Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilities and end-to-end services required in the rapidly evolving biopharmaceutical industry. The launch of Q2Solutions is the result of the close of the previously announced global clinical trials laboratory services joint-venture transaction.
Global CRO Quintiles has added advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics combine Quintiles’ experience in RBM with its therapeutic and statistical sciences heritage to enable study teams to identify the right signals and predict clinical trial site performance and potential patient safety issues.
Global CRO Quintiles is extending its Quintiles Infosario technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.
The Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites, has announced a program for the 2015 Asia-Pac Site Solutions Summit. The Asia-Pac Site Solutions Summit will be July 30-31, 2015 in Melbourne, Australia. The Summit is open to clinical research investigators, site executives and industry stakeholders.
Following the completion of the management buyout of Synexus, the new board confirms its intention to expand the footprint of the company through organic growth and acquisition. Synexus, a multi-national company dedicated to the recruitment and running of clinical trials at its own research centers across the globe, intends to become a major player in the U.S., continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.